SweDeliver
Research forum in drug delivery, focusing on new strategies for parenteral, oral and pulmonary drug delivery.
News
- Successful Pharmaceutical summit at Uppsala Konsert & Kongress 2023-11-30
- 60 million to new Nordic life science consortium with node at the Faculty of Pharmacy 2023-11-23
- SweDeliver welcomes Chiesi as a new industrial partner 2023-11-07
- Half-time seminar • Xiguo He: New platform for optimal absorption of oral antibiotics 2023-10-30
- Half-time seminar with Marco Tjakra: Artificial colonic mucus for studies of the mucus absorption barrier in vitro 2023-10-13
Seminars & Events
Pharmaceutical summit
at Uppsala University
"The three day conference was an absolute success"
SweDeliver welcomes
New Partner: Chiesi
"Puts another quality stamp on our center's research and training"
SweDeliver welcomes
Our new researchers
Yassir Al-Tikriti, Anton Norberg and David Juriga
NSSM–2024
9–10 January 2024
Registration & Abstract submission to NSSM–2024 is now open
This is SweDeliver
SweDeliver is a world leading research and competence centre in Drug Delivery. Many novel molecules in the drug discovery and development pipeline are biological compounds such as proteins, peptides and RNA. These display problems of poor solubility, membrane permeability and low bioavailability. Thus, the Drug Delivery area is today facing tremendous challenges to develop new drug therapies.
SweDeliver was established in response to these challenges. Based on a multi-disciplinary collaboration between academia and industry with financial support from Vinnova (Sweden’s Innovation Agency), the Faculty of Pharmacy at Uppsala University is the academic hub of the Centre with 17 industrial partners contributing expertise and research infrastructure as well as industrial perspectives and needs within the three main research areas of the Centre.
SweDeliver has prioritized to focus on outstanding research challenges within
- Parenteral Drug Delivery
- Oral Drug Delivery
- Pulmonary Drug Delivery
The research will ultimately lead to development of new and improved drug therapies with respect to both efficacy and patient safety. The Centre will also further support the strong research environment and the drug delivery ecosystem in the Nordic region.
